Journal of Cancer Therapeutics and Immunotherapy

ABSTRACT

Ovarian cancer is a largely murderous gynecologic malice, with inheritable and molecular mutations playing a vital part in its pathogenesis and progression. This composition explores the crucial inheritable mutations associated with ovarian cancer, including BRCA1, BRCA2, and other less common but significant mutations similar as TP53, PTEN, and KRAS. The focus is on understanding how these mutations contribute to excrescence development, treatment resistance, and prognostic. Advances in inheritable testing and targeted curatives, including PARP impediments, have converted the operation of ovarian cancer, offering individualized treatment options and bettered issues. Ethical considerations, similar as inheritable comforting and threat operation for carriers, are also bandied. This review aims to give a comprehensive overview of the molecular underpinnings of ovarian cancer mutations and their clinical counteraccusations.

KEYWORDS

1. Prognosis
2. Genetic counseling
3. Tumor development
4. Ovarian cancer
5. BRCA1